Crucell Announces PER.C6 Licensing Agreement with Novartis

Published on: 

Dutch biotechnology company Crucell N.V. (Leiden, the Netherlands, www.crucell.com) and Novartis Vaccines and Diagnostics, Inc. (Basel, Switzerland, www.novartis.com), have extended a nonexclusive research license agreement for PER.C6.

Dutch biotechnology company Crucell N.V. (Leiden, the Netherlands, www.crucell.com) and Novartis Vaccines and Diagnostics, Inc. (Basel, Switzerland, www.novartis.com), have extended a nonexclusive research license agreement for PER.C6. The license agreement allows Novartis to use Crucell’s PER.C6 cell technology in manufacturing alphavirus vectors for its vaccine research programs. The PER.C6 technology is a human cell line developed for the development and large-scale manufacture of biopharmaceutical products including vaccines.